Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962199 | 1.00 | PPARG (0.39) | PPARGPOLBALDH1A1HPGDNR3C1 | |
| SCHEMBL964540 | 0.95 | PPARG (0.43) | PPARGPOLB | |
| SCHEMBL964538 | 0.95 | PPARG (0.43) | PPARGPOLB | |
| SCHEMBL965341 | 0.94 | PPARG (0.46) | PPARG | |
| SCHEMBL965343 | 0.94 | PPARG (0.46) | PPARG | |
| SCHEMBL968581 | 0.88 | PPARG (0.37) | PPARGALDH1A1HPGDNR3C1 | |
| SCHEMBL968579 | 0.88 | PPARG (0.37) | PPARGALDH1A1HPGDNR3C1 | |
| SCHEMBL968569 | 0.88 | PPARG (0.35) | PPARGPOLBALDH1A1HPGDNR3C1 | |
| SCHEMBL968568 | 0.88 | PPARG (0.35) | PPARGPOLBALDH1A1HPGDNR3C1 | |
| SCHEMBL27793887 | 0.87 | PPARG (0.36) | PPARGPOLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | PPARG 248/4885POLB 3524/4885ALDH1A1 421/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | PPARG 3/4885POLB 1580/4885ALDH1A1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.